Leadless Cardiac Pacemaker Deemed Safe, Effective

This article originally appeared here.
Share this content:
Leadless Cardiac Pacemaker Deemed Safe, Effective
Leadless Cardiac Pacemaker Deemed Safe, Effective

MONDAY, Aug. 31, 2015 (HealthDay News) -- For patients who require permanent single-chamber ventricular pacing, an active-fixation leadless cardiac pacemaker is safe and effective, according to a study published online Aug. 30 in the New England Journal of Medicine. The study was published to coincide with the annual European Society of Cardiology Congress, held from Aug. 29 to Sept. 2 in London.

Vivek Y. Reddy, M.D., from the Icahn School of Medicine at Mount Sinai in New York City, and colleagues conducted a multicenter study to evaluate the efficacy of an active-fixation leadless cardiac pacemaker implanted in patients who required permanent single-chamber ventricular pacing.

The researchers found that the leadless pacemaker was successfully implanted in 95.8 percent of the 526 patients in the total cohort. In 90 percent of the 300 patients in the primary cohort, the intention-to-treat primary efficacy end point was met (acceptable pacing threshold and acceptable sensing amplitude through six months: P = 0.007), while the primary safety end point was met by 93.3 percent (freedom from device-related serious adverse events through six months: P < 0.001). Device-related serious adverse events occurred in 6.7 percent of patients at six months.

"The leadless cardiac pacemaker met prespecified pacing and sensing requirements in the large majority of patients," the authors write. "Device-related serious adverse events occurred in approximately one in 15 patients."

The study was funded by St. Jude Medical.

Abstract
Full Text
More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Incident Contrast Sensitivity Common in Middle-Aged Adults

Incident Contrast Sensitivity Common in Middle-Aged Adults

Factors linked to elevated risk include cadmium level in highest quintile, older age, more plaque sites

Tafamidis Treats Transthyretin Amyloid Cardiomyopathy

Tafamidis Treats Transthyretin Amyloid Cardiomyopathy

Reduces all-cause mortality, cardiovascular-related hospitalizations compared with placebo

Scribes Improve Physician Workflow, Patient Interaction

Scribes Improve Physician Workflow, Patient Interaction

Scribes lower EHR documentation burden for doctors and increase time spent interacting with patients

is free, fast, and customized just for you!




Already a member?

Sign In Now »